Go Medical is a manufacturer of medical devices and accessories for the company’s Infusion business.
Admedus’s CEO Wayne Paterson said: “The company believes that this outcome is in the best interest of all stakeholders in the short, medium, and long-term.
“While this may have a short-term impact on the timing of breakeven earnings, the company still aims to be profitable for 2019.
“We have a great team in place who consistently deliver above-target sales revenue and offer premium service to our valued customers.”
Adequate supply to meet near-term demand
Admedus is committed to working closely with existing customers and Go Medical as it transitions the business, and confirms it has adequate supply to meet demand during the 45-day completion period.
This change in the supplier arrangement is expected to have a 5.7% impact on top-line revenue for the financial year.
It is important to note that this change relates only to the supply of smaller intravenous consumable medical products, and has no impact on Admedus’ distribution of infusion pumps to major hospitals.
Admedus making changes to be more competitive
Under the leadership of its new business unit head, Glenn Gilchrist, Admedus has been refreshing its long-term strategic plan for the Infusion business.
This includes assessing its capabilities, organisational footprint, and product portfolio.
The review identified certain products and pricing within the portfolio which needed to be more competitive.
Admedus engaged Go Medical on these topics, seeking a mutually beneficial outcome, but unfortunately were unable to reach agreement.